文献速递胸部肿瘤

免疫检查点在非小细胞肺癌肿瘤中共表达的免疫组化与图像分析研究

Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
PubMed 文献 · J Thorac Oncol · 2018-03-08

该研究对225例I-III期非小细胞肺癌(142例腺癌和83例鳞癌)组织芯片进行9种免疫检查点标记的定量图像分析,发现鳞癌中免疫检查点表达高于腺癌,腺癌中常见PD-L1+B7-H3+IDO-1共表达,鳞癌中常见PD-L1+B7-H3或B7-H3+B7-H4共表达,且表达与吸烟史、肿瘤大小、炎症细胞密度及KRAS突变状态相关。

要点

  • 鳞癌免疫检查点表达高于腺癌,腺癌常见PD-L1+B7-H3+IDO-1共表达。
  • 鳞癌常见PD-L1+B7-H3或B7-H3+B7-H4共表达。
  • 腺癌中B7-H4高表达提示预后更差。

核心结论

  • 手术切除的非小细胞肺癌肿瘤中免疫检查点频繁共表达,并与组织学类型、吸烟史、肿瘤大小、炎症细胞密度及肿瘤突变状态相关。

研究设计与样本

  • 研究纳入225例I-III期非小细胞肺癌(142例腺癌和83例鳞癌)的福尔马林固定石蜡包埋组织,置于组织芯片中。
  • 评估9种免疫检查点标记,其中4种主要表达于恶性细胞,5种主要表达于基质肿瘤相关炎症细胞。
  • 所有标记采用定量图像分析,并与临床病理特征、肿瘤相关炎症细胞及分子特征进行相关性分析。

主要发现

  • 以高于中位值作为恶性细胞阳性表达及表达标记的肿瘤相关炎症细胞高密度,鳞癌免疫检查点表达高于腺癌。
  • 腺癌中恶性细胞常见同时表达PD-L1、B7-H3和IDO-1;鳞癌中常见PD-L1+B7-H3或B7-H3+B7-H4。
  • 表达检查点的肿瘤相关炎症细胞在当前吸烟者中显著高于从不吸烟者。
  • 几乎所有免疫检查点标记与表达炎症细胞标记的肿瘤相关炎症细胞呈正相关。
  • KRAS突变腺癌标本中恶性细胞PD-L1表达及肿瘤相关炎症细胞中B7-H3、T细胞免疫球蛋白黏蛋白家族成员3和IDO-1表达高于野生型。

临床怎么用

  • 非小细胞肺癌中多种免疫检查点共表达常见,支持设计联合免疫治疗策略时考虑多个靶点。
  • 腺癌中B7-H4高表达与预后更差相关,可能作为预后评估的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The understanding of immune checkpoint molecules' co-expression in non-small cell lung carcinoma (NCLC) is important to potentially design combinatorial immunotherapy approaches. METHODS: We studied 225 formalin-fixed, paraffin-embedded tumor tissues from stage I-III NCLCs - 142 adenocarcinomas (ADCs) and 83 squamous cell carcinomas (SCCs) - placed in tissue microarrays. Nine immune checkpoint markers were evaluated; four (programmed death ligand 1 [PD-L1], B7-H3, B7-H4, and indoleamine 2,3-dioxygenase 1 [IDO-1]) expressed predominantly in malignant cells (MCs) and five (inducible T cell costimulator, V-set immunoregulatory receptor, T-cell immunoglobulin mucin family member 3, lymphocyte activating 3, and OX40) expressed mostly in stromal tumor-associated inflammatory cells (TAICs). All markers were examined using a quantitative image analysis and correlated with clinicopathologic features, TAICs, and molecular characteristics. RESULTS: Using above the median value as positive expression in MCs and high density of TAICs expressing those markers, we identified higher expression of immune checkpoints in SCC than ADC. Common simultaneous expression by MCs was PD-L1 + B7-H3 + IDO-1 in ADC and PD-L1 + B7-H3, or B7-H3 + B7-H4, in SCC. TAICs expressing checkpoint were significantly higher in current smokers than in never smokers. Almost all the immune checkpoint markers showed positive correlation with TAICs expressing inflammatory cell markers. KRAS-mutant ADC specimens showed higher expression of PD-L1 in MCs and of B7-H3, T-cell immunoglobulin mucin family member 3, and IDO-1 in TAICs than wild type. Kaplan-Meier survival curves showed worse prognosis in ADC patients with higher B7-H4 expression by MCs. CONCLUSIONS: We found frequent immunohistochemical co-expression of immune checkpoints in surgically resected NCLC tumors and correlated with tumor histology, smoking history, tumor size, and the density of inflammatory cells and tumor mutational status.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Parra ER, Villalobos P, Zhang J, et al. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018. PMID: 29526824. doi:10.1016/j.jtho.2018.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。